| A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing D Pan, A Kobayashi, P Jiang, L Ferrari de Andrade, RE Tay, AM Luoma, ... Science 359 (6377), 770-775, 2018 | 716 | 2018 |
| A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer DY Takeda, S Spisák, JH Seo, C Bell, E O’Connor, K Korthauer, D Ribli, ... Cell 174 (2), 422-432. e13, 2018 | 276 | 2018 |
| Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations R Jeselsohn, JS Bergholz, M Pun, MI Cornwell, W Liu, A Nardone, T Xiao, ... Cancer cell 33 (2), 173-186. e5, 2018 | 236 | 2018 |
| Prostate cancer reactivates developmental epigenomic programs during metastatic progression MM Pomerantz, X Qiu, Y Zhu, DY Takeda, W Pan, SC Baca, A Gusev, ... Nature genetics 52 (8), 790-799, 2020 | 183 | 2020 |
| VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis MI Cornwell, M Vangala, L Taing, Z Herbert, J Köster, B Li, H Sun, T Li, ... BMC bioinformatics 19, 1-14, 2018 | 168 | 2018 |
| EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer KL Morel, AV Sheahan, DL Burkhart, SC Baca, N Boufaied, Y Liu, X Qiu, ... Nature cancer 2 (4), 444-456, 2021 | 137 | 2021 |
| Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer S Shu, HJ Wu, YG Jennifer, R Zeid, IS Harris, B Jovanović, K Murphy, ... Molecular cell 78 (6), 1096-1113. e8, 2020 | 130 | 2020 |
| Integrative analyses of single-cell transcriptome and regulome using MAESTRO C Wang, D Sun, X Huang, C Wan, Z Li, Y Han, Q Qin, J Fan, X Qiu, Y Xie, ... Genome biology 21, 1-28, 2020 | 128 | 2020 |
| A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2) YZ Mazzu, J Armenia, G Chakraborty, Y Yoshikawa, SAA Coggins, ... Clinical Cancer Research 25 (14), 4480-4492, 2019 | 119 | 2019 |
| Targetable vulnerabilities in T-and NK-cell lymphomas identified through preclinical models SY Ng, N Yoshida, AL Christie, M Ghandi, NV Dharia, J Dempster, ... Nature communications 9 (1), 2024, 2018 | 93 | 2018 |
| Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer SC Baca, DY Takeda, JH Seo, J Hwang, SY Ku, R Arafeh, T Arnoff, ... Nature communications 12 (1), 1979, 2021 | 88 | 2021 |
| Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer P Cejas, Y Xie, A Font-Tello, K Lim, S Syamala, X Qiu, AK Tewari, N Shah, ... Nature communications 12 (1), 5775, 2021 | 74 | 2021 |
| MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets X Qiu, N Boufaied, T Hallal, A Feit, A de Polo, AM Luoma, W Alahmadi, ... Nature communications 13 (1), 2559, 2022 | 70 | 2022 |
| Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling H Singhal, ME Greene, AL Zarnke, M Laine, R Al Abosy, YF Chang, ... Oncotarget 9 (4), 4282, 2018 | 62 | 2018 |
| CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity AC Watt, P Cejas, MJ DeCristo, O Metzger-Filho, EYN Lam, X Qiu, ... Nature Cancer 2 (1), 34-48, 2021 | 58 | 2021 |
| CREB5 promotes resistance to androgen-receptor antagonists and androgen deprivation in prostate cancer JH Hwang, JH Seo, ML Beshiri, S Wankowicz, D Liu, A Cheung, J Li, ... Cell reports 29 (8), 2355-2370. e6, 2019 | 51 | 2019 |
| Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ L Ding, Y Su, A Fassl, K Hinohara, X Qiu, NW Harper, SJ Huh, ... Nature communications 10 (1), 4182, 2019 | 48 | 2019 |
| TRPS1 is a lineage-specific transcriptional dependency in breast cancer RM Witwicki, MB Ekram, X Qiu, M Janiszewska, S Shu, M Kwon, A Trinh, ... Cell reports 25 (5), 1255-1267. e5, 2018 | 48 | 2018 |
| Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence Z Wu, J Zhou, X Zhang, Z Zhang, Y Xie, J Liu, ZV Ho, A Panda, X Qiu, ... Nature genetics 53 (6), 881-894, 2021 | 46 | 2021 |
| Androgen receptor is a non-canonical inhibitor of wild-type and mutant estrogen receptors in hormone receptor-positive breast cancers S Ponnusamy, S Asemota, LS Schwartzberg, F Guestini, KM McNamara, ... Iscience 21, 341-358, 2019 | 29 | 2019 |
